[6]Foxman B . Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden[J].Infect Dis Clin North Am. 2014;28(1):1-13. doi: 10.1016/j.idc.2013.09.003 . [7]McGovern AP , Hogg M , Shields...
Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database https://pubmed.ncbi.nlm.nih.gov/33606891/
SGLT2 Inhibitor and Urinary Tract Infection in Men at Risk for Voiding Dysfunction: A VigiBase Analysisdoi:10.1097/UPJ.0000000000000698sodium-glucose cotransporter-2 (SGLT2) inhibitorsurinary tract infectionmen’s healthbenign prostate hyperplasia
13. Fralick M, MacFadden DR. A hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection. Diabetes Obes Metab. 2020;22:755–758. 14. Suzuki M, Hiramatsu M, Fuk...
参考资料: Diabetes Obes Metab. 2020 May;22(5):755-758. A hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection. https://pubmed.ncbi.nlm.nih.gov/31943733...
Finerenone had the lowest incidence of urinary tract infection, Hypoglycemia was the lowest in the Luseogliflozin group. Ertugliflozin was the least likely to cause acute kidney injury. Canagliflozin had the lowest probability of any adverse event. Conclusion: The safety of...
The most common adverse events reported was increased risk of genitourinary infection, which included genital mycotic and urinary tract infections. Most of the data from the studies comparing individuals with/without T2D came from a subgroup analysis, so it could have affected the outcomes of the ...
Moreover, the proportion of patients with genital infection and urinary tract infections, adverse events that can occur according to the mechanism of SGLT2 inhibitors, was only 2%, verifying outstanding safety of the drug. This is a signif...
For genitourinary tract infection or recurrent infection within half a year, SGLT2i should be used cautiously or not recommended. However, some major outcome trials suggest that SGLT2i are not associated with an increased risk of urinary tract infections (UTIs) [31,32,33]. Wilding et al. ...
The most common adverse effect of SGLT2i is urinary tract infections3. A less common yet equally important side-effect associated with SGLT2i is DKA. SGLT-2 associated DKA is not an extensively studied phenomenon4. DKA is more common in type 1 diabetes mellitus (T1D) than T2D (50–100...